Contribute Try STAT+ Today

After the World Health Organization recommended a Roche (RHHBY) drug to treat severe Covid-19, Doctors Without Borders quickly urged the drug maker to “end its monopoly” by lowering the price of the medicine and sharing its technology in order to quickly widen access.

Meta-analyses of more than 10,000 patients who were enrolled in 27 clinical trials founds that two medicines — Roche’s Actemra and Kevzara from Sanofi — lowered the risk of death by 13% compared to standard care, especially when given with corticosteroids. The WHO noted these were the first drugs to be found effective against Covid-19 since corticosteroids were recommended last September.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment